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Abstract
Human stem cells are in evaluation in clinical stem cell trials, primarily as autologous bone marrow
studies, autologous and allogenic mesenchymal stem cell trials, and some allogenic neural stem cell
transplantation projects. Safety and efficacy are being addressed for a number of disease state
applications. There is considerable data supporting safety of bone marrow and mesenchymal stem
cell transplants but the efficacy data are variable and of mixed benefit. Mechanisms of action of many
of these cells are unknown and this raises the concern of unpredictable results in the future.
Nevertheless there is considerable optimism that immune suppression and anti-inflammatory
properties of mesenchymal stem cells will be of benefit for many conditions such as graft versus
host disease, solid organ transplants and pulmonary fibrosis. Where bone marrow and
mesenchymal stem cells are being studied for heart disease, stroke and other neurodegenerative
disorders, again progress is mixed and mostly without significant benefit. However, correction of
multiple sclerosis, at least in the short term is encouraging. Clinical trials on the use of embryonic
stem cell derivatives for spinal injury and macular degeneration are beginning and a raft of other
clinical trials can be expected soon, for example, the use of neural stem cells for killing inoperable
glioma and embryonic stem cells for regenerating β islet cells for diabetes. The change in attitude
to embryonic stem cell research with the incoming Obama administration heralds a new co-
operative environment for study and evaluation of stem cell therapies. The Californian stem cell
initiative (California Institute for Regenerative Medicine) has engendered global collaboration for
this new medicine that will now also be supported by the US Federal Government. The active
participation of governments, academia, biotechnology, pharmaceutical companies, and private
investment is a powerful consortium for advances in health.
Commentary
There are some major changes happening in stem cell
therapies that are setting a new paradigm for regenerative
medicine. The opportunity to repair and regenerate tissues
injured by disease and trauma is opening the way to new
optimistic treatments that need to be carefully evaluated
in early clinical trials. These developments are building on
the successes of bone marrow hematopoietic stem cell
(HSCs) transplants that have more than 30 years of
patient applications in blood diseases and cancer. The
bulk of applications of the new stem cell therapies follow
the expected route of autologous transplants, to avoid
severe immune suppression that commonly applies to all-
ogenic cell transplantation. However, autologous thera-
pies require the recovery of the patient's own
hematopoietic, endothelial or mesenchymal stem cells by
bone marrow biopsy, mobilization of bone marrow stem
cell types by administration of recombinant growth fac-
tors, and isolation of multipotent stem cells from adipose
tissue.
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These autologous stem cell therapies are in widespread
clinical trials with varying reported clinical benefits to
patients. Reports on the use of granulocyte-colony stimu-
lating factor mobilization of bone marrow stem cells and
the intracoronary administration of leukapheretically iso-
lated HSCs, show a few subjective benefits but overall no
real objective benefit in refractory ischemic heart disease
[1]. Some consistency in benefit in left ventricular func-
tion and remodeling has been observed in studies of intra-
coronary administration of the patient's own bone
marrow preparations for severe myocardial infarction [2].
There is also evidence in the few comparative clinical stud-
ies available that the endothelial (CD34+) fraction of
mononuclear bone marrow cells is the potent cell type
responsible for vascular growth and regeneration and the
clinical improvements observed in cardiac repair [3].
Aside from autologous adult stem transplants that are
based mainly on the use of bone marrow, where is the
field moving (Figure 1)? There is an increasing interest in
allogenic stem cell therapies and advantage is being taken
of cell therapies using mesenchymal (bone marrow stro-
mal) stem cells (MSCs), which have both multipotential
(by definition are capable of forming bone, adipose, and
cartilage tissue), and immunosuppressive properties. The
latter enables their grafting without the need for severe
immunosupression and selection for histocompatibilty.
These clinical trials are being led by the biotechnology
companies, Osiris (Columbia, MD, USA) and Angioblast
(New York, USA)/Mesoblast (Melbourne, Australia) for
primary applications in preventing graft versus host dis-
ease (GvH) and treatment of cardiovascular and bone dis-
eases. Cartilage repair using MSCs is still in preclinical and
phase I studies with no detailed comparative data in
humans [4]. Other very accessible sources of MSCs with
Human stem cell transplants Figure 1
Human stem cell transplants. Bone marrow cells are mobilized and recovered for autologos transplantation for a number 
of applications, including cancer, blood diseases, stroke and multiple sclerosis. Allogenic stem cells are frequently recovered 
from the placenta and umbilical cord. Mesenchymal stem cells are used for immune suppression and inflammatory conditions. 
Neural stem cells are of fetal origin or differentiated from embryonic stem (ES) cells and induced pluripotential stem (iPS) cells. 
Both ES and iPS cells are poised for clinical trials for repair of spinal injury, macular degeneration, diabetes and cancer.BMC Medicine 2009, 7:29 http://www.biomedcentral.com/1741-7015/7/29
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apparently equivalent biological function have been iden-
tified, including the placenta [5] and Wharton's jelly of
the human umbilical cord [6]. The use of cord blood cells
in adults may be often accompanied by central nervous
complications [7] and the need for enhancement of adap-
tive immunity without GvH. These conditions may be
improved clinically by co-infusion of MSCs with cord
blood cells [8].
Perhaps more challenging is the use of bone marrow
derivatives for neural degenerative disorders. Autologous
non-myeloablative HSC transplantation (mononucleo-
cytes and platelets) has been undertaken, for example in
21 patients with relapsing-remitting multiple sclerosis to
reverse neurological deficits [9]. The benefits are derived
presumably from the MSC-induced immune suppression
and inhibition of the proliferation of alloreactive T cells
observed both in vitro and in vivo [10]. Similarly, benefits
have been observed for steroid resistant GvH disease using
MSCs [11,12], and also severe inflammatory diseases such
as idiopathic pulmonary fibrosis [13]. While these reports
are encouraging, further development and improvement
of efficacy is needed because the use of MSCs for GvH and
inflammatory disease is not as yet able to completely
replace more conventional approaches that limit their
severity [14]. Likewise, solid organ transplantation
accompanied by MSC administration limits the prolifera-
tion of alloactivated T cells as shown in studies with kid-
ney transplantation [15]. Concerns remain that while
MSC administration is safe and potentially effective, the
mixed results, that is, lack of demonstrated functionality
and absence of long-term integration of MSC derivatives,
are distinctly of issue [16].
It is also proposed that bone marrow stem cell mobiliza-
tion be used to treat stroke despite little understanding of
the possible mechanisms that may be involved. Clinical
trials are underway and there is optimism that benefits
will be clearly demonstrated [17]. Some attempts are
being made to coordinate and standardize methods and
assessments to enable a better determination of clinical
benefit across trials, an issue that has been a constant dif-
ficulty for interpreting benefit in stem cell trials [18].
Neural stem cells (NSCs) are being explored for the treat-
ment of lysosomal storage diseases in very young patients.
The biotechnology company California Stem Cells Inc.
(Irvine, CA, USA) is using transplantation of fetal NSCs
for children with Batten's disease. This is an important
study that addresses a very difficult genetic disease. While
some benefits are reported for pharmacological enzyme
replacement therapy for lysosomal storage diseases [19],
long-term therapy is likely to be restricted to cell-based
approaches. It is also of interest that NSCs have a remark-
able tropism for malignant gliomas. Consequently, NSCs
are a very likely vector to deliver oncolytic agents such as
the intra-tumoral herpes simplex virus thymidine kinase
[20]. There is strong interest in targeting inoperable glio-
balatomas using this strategy with a range of engineered
NSCs that will be seeking clinical trial approval in the near
future. Some concern was raised by the report of solid
multifocal brain tumor in a child with ataxia telangiecta-
sia treated with intracerebellar and intrathecal injections
of fetal NSCs in a clinic in Russia [21]. The glioneuronal
neoplasm was of donor origin. There is little known of the
methods used in this clinic and no reports in a large
number of fetal brain tissue transplants in studies from
other clinics. Nevertheless, continued vigilance in clinical
trials is needed to ensure safety in all types of stem cell
transplantation.
Clinical studies on the use of pluripotential stem cells are
beginning. The first approved clinical trial by the Food
and Drug Administration (FDA) using embryonic stem
cell-derived products is for complete spinal cord injury
involving low lumbar injection of glial oligodendrocytes
by the biotechnology company Geron (Menlo Park, CA,
USA) [22]. Their trial is in phase I testing for safety and
will involve a small number of patients [23]. The Interna-
tional Society of Stem Cell Research has released guide-
lines for translational and preclinical research to ensure
the global scientific community has a benchmark for the
scientific and ethical principles involved in applying
pluripotential stem cells for clinical treatments in regener-
ative medicine [24]. Many other applications are expected
to enter clinical trial from embryonic stem cells (ESCs) or
the new induced pluripotential stem cells (iPSCs) that are
reprogrammed from mature adult cells by transduction
with transcription factor DNA [25] or recombinant tran-
scription factor proteins [26].
ESCs, and potentially iPSCs, can be directed into a wide
range of cell types and proof of concept studies are taking
place for preclinical studies to correct human diseases in
animal models of a variety of conditions, including diabe-
tes [27], myocardial infarction [28], Parkinson's disease
[29], and liver disease [30]. One of the leading opportuni-
ties is for correction of loss of central vision through age-
related macular degeneration. Human ESCs form retinal-
pigmented epithelium relatively easily and research is rap-
idly progressing in vitro and in vivo preclinical trials. Dif-
ferentiating retinal epithelial cells produce a regular,
polarized monolayer with developmentally important
apical and basal features consistent with developing ret-
ina, and on transplantation, rhodopsin-positive material
is observed that is required of regenerating vision [31].
Regulatory approval is being sought for clinical trials fol-
lowing very encouraging preclinical studies in animals for
the correction of blindness associated with retinal loss.
Importantly, the pharmaceutical company Pfizer (Sand-BMC Medicine 2009, 7:29 http://www.biomedcentral.com/1741-7015/7/29
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wich, UK) has joined the British group pioneering these
studies and both Pfiza and Johnson & Johnson (Lang-
horne, PA) have links to the Californian biotechnology
company Novocell (Irvine, CA) who are developing β islet
cells derived from human ESCs for correction of diabetes.
Clinical trial approval may be expected to be sought from
the FDA by Novocell in the near future.
The changes that have just occurred in the US Federal
Administration following the election of President
Obama are substantial and important. The removal of the
presidential proclamation that hindered the support of
human ESC research through the US National Institutes of
Health (NIH) has galvanized the scientific and biotech-
nology communities to accelerate progress on basic
research and to stimulate translational work for regulatory
approval. The Californian Institute for Regenerative Med-
icine (CIRM), charged with directing the US$3 billion of
research funding on stem cell research, has just
announced US$68 million for translational projects to
complement the very substantial support of basic
research, training and facilities (>US$600 million)
awarded over the last 3 years. CIRM is also in the process
of previewing responses for the call for preclinical 'disease
team' projects that will be each funded up to US$20 mil-
lion for 4 years. These projects are expected to submit for
regulatory approval for clinical trials within the next 4
years. It is expected that with encouragement from CIRM,
NIH, and the FDA, given the new federal administrative
backing, there will be an escalation of clinical trial sub-
missions involving pluripotent ESCs and iPSCs, multipo-
tent placental, and adult and fetal stem cells. The
challenge will remain to evaluate their effectiveness and
safety, compared with any other treatments that are cur-
rently available. The need for investment for clinical trial
support will be limiting unless the government and health
insurance industry joins pharmaceutical and biotechnol-
ogy industries to carry out the large variety of trials
expected. Academic and medical research centers are also
expected to be involved in the translation and clinical trial
processes which heralds new opportunities for teamwork
approaches for these new cell therapies.
There are also changes in interest for collaborations
nationally and internationally. CIRM has collaborative
agreements for joint funding of research projects with the
UK, Spain, Canada, the State of Victoria in Australia, and
Japan. The State of Victoria has been successful in the
award of joint funding with CIRM for early translational
grants, and the UK, Canada, and Spain are participating in
the disease team applications. CIRM expects to work
together with the NIH to promote national collaborations
in stem cell research and has formulated a program of
loans to support Californian companies working in stem
cell science. The amalgamation of all these interests pro-
vides an extremely healthy environment for the global
endeavor to deliver cell and related therapies to patients.
In conclusion, the field of stem cell sciences is rapidly
integrating as new clinical trials of adult bone marrow,
MSCs and NSCs for treatment of a variety of pathologies
that build on more than 30 years of experience of treating
blood diseases and cancer with HSCs. These new trials
include many allogenic cell therapies that are more chal-
lenging than the autologous cell therapies, but within the
next 10 years these will be the platform for the newly
evolving pluripotential stem cell therapeutics. The latter
presently involves ESCs differentiated to NSCs, glial and
neuronal lineages, retinal epithelium, β islet cells, cardio-
myocytes, hepatocytes, blood cells, and many other cell
types and engineered tissue. Since the initial trials with
patients will be phase I studies, which address safety
issues, it is expected that useful clinical data on cell thera-
peutic effectiveness will not really be available for 5 to 10
years. While this may sound to be a long time, it is the
established processes for trials that developments from
discovery to clinical acceptance are generally 20 years or
more. The therapies that will emerge first are likely to
address neural repair, macular degeneration, cancer tar-
geting, problems of immunity, and cardiovascular dis-
ease. However, the validity of these predictions will
depend on the benefits obtained in the human phase II
and III clinical trials that are still some time away. In the
meantime, new candidate small molecules and bioactives
are being identified using stem cell assays in high
throughput screening that will impact on stem cell mobi-
lization and expansion for regenerative medicine. Person-
alized medicine will also undergo a revolution with the
use of iPSCs for analyzing disease heterogeneity and vari-
able drug response.
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